SGI Venture Capital
VC Fund
Seoul, South Korea
SGI Venture Capital is a VC fund in Seoul focused on Medical and Software. Founded in 2007, SGI (Samho Green Investment) is the first and only venture capital firm in Korea focused on the green growth sector, including renewable energy, green and agricultural technologies. We engage in venture capital and private equity investments for mergers & acquisitions and buyouts, and conduct business as well as engineeringconsulting for our portfolio and client companies.Our investment focus areas are green technology (greentech) commercialization, green infrastructure and agricultural technologies (agritech), as well as early-stage project development. We have an experienced team of in-house greentech specialists and an extensive domestic and international greentech network, which assists us in deal sourcing, value creation and exit management.
- Total investments:
- 44
- Last investment:
- Lead investor:
- 11%
- Fund size:
- $27k
- Last fund:
Last updated:
For AI agents: llms.txt
Industries SGI Venture Capital invests in
Stages SGI Venture Capital invests in
Countries SGI Venture Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $962k–$6M
- Series A
- $1.2M–$17M
- Series B
- $1.1M–$47M
Investment Focus
Industry
- Medical 8 (18%)
- Software 4 (9%)
- Health Care 4 (9%)
- Biotechnology 4 (9%)
- Therapeutics 3 (7%)
Stage
- Series A 15 (34%)
- Series B 6 (14%)
- Seed 4 (9%)
- Funding Round 3 (7%)
- Series C 2 (5%)
Country
- South Korea 25 (57%)
- Singapore 1 (2%)
- United States 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jiyoung Tim Kang
Executive Managing Director
|
Executive Managing Director | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Airbility
|
Airability is a developer for potential airline mobility solutions. | $4.7M / Series A / Sep 01, 2026 | |
FNCT Biotech
|
FNCT Biotech develops antibody therapeutics for treating idiopathic pulmonary fibrosis (IPF). To create antibodies that target the underlying cause of IPF, the company's platform uses genetic engineering, providing patients with this medical need with a new treatment option. | $14M / Series B / Jun 16, 2026 | |
Solivis
|
Solivis is the manufacturer of solid-state batteries designed for next-generation battery packs. The company's product is used as a secondary battery for electric vehicles and has developed a wet synthesis method that can mass-produce a sulfide-based solid electrolyte with homogeneous high ionic conductivity, enabling clients to significantlyimprove productivity by reducing process costs and shortening the synthesis time. | $13.7M / Series C / Jun 04, 2026 | |
Unastella
|
Unastella is an aerospace company developing human spaceflight technologies, including launch vehicles and suborbital tourism systems. The company focuses on advancing reusable rocket technology and future space travel infrastructure for civilian space exploration missions. Unastella aims to support the growth of private human spaceflight andnext-generation aerospace innovation. | $22.2M / Series B / Jun 01, 2026 | |
PineTree Therapeutics
|
PineTree Therapeutics engages in the development of disruptive therapies in Oncology and Immuno-oncology. | $47M / Series B / Oct 28, 2025 | |
Bem Robotics
|
Bem Robotics is developer of indoor industrial robotics technology designed to improve automated material handling and operational control | $3.6M / Series A / Aug 18, 2025 | |
Dime Bio
|
Dime Bio is a drug development company for novel dementia treatments. | $8.2M / Series A / Mar 26, 2025 | |
|
Airbility
|
Airability is a developer for potential airline mobility solutions. | $1.7M / Series A / Jan 22, 2025 | |
|
Airbility
|
Airability is a developer for potential airline mobility solutions. | $1.7M / Seed / Jan 22, 2025 | |
Soomvi
|
Soomvi is an industrial drone market company that provides marine lifesaving system services. | $5.5M / Venture - Series Unknown / Dec 23, 2024 | |
| See all 44 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does SGI Venture Capital invest in?
SGI Venture Capital invests primarily in Medical, Software and Health Care startups, most often at Series A and Series B stage. Most of the 44 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is SGI Venture Capital's check size?
SGI Venture Capital typically joins rounds of $962k–$6M at Seed, $1.2M–$17M at Series A and $1.1M–$47M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SGI Venture Capital participates in.
How do I contact SGI Venture Capital?
Public channels for SGI Venture Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SGI Venture Capital?
The team at SGI Venture Capital includes Jiyoung Tim Kang (Executive Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
